Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Heart failure outcomes in clinical trials of glucose‐lowering agents in patients with diabetes
David Fitchett, Jacob A. Udell, Silvio E. Inzucchi
European Journal of Heart Failure (2016) Vol. 19, Iss. 1, pp. 43-53
Open Access | Times Cited: 97

Showing 1-25 of 97 citing articles:

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca, et al.
New England Journal of Medicine (2018) Vol. 380, Iss. 4, pp. 347-357
Open Access | Times Cited: 5168
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus
Karin Rådholm, Gemma A. Figtree, Vlado Perkovic, et al.
Circulation (2018) Vol. 138, Iss. 5, pp. 458-468
Open Access | Times Cited: 436
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
Yuliya Lytvyn, Petter Bjornstad, Jacob A. Udell, et al.
Circulation (2017) Vol. 136, Iss. 17, pp. 1643-1658
Open Access | Times Cited: 394
Highlights in heart failure
Daniela Tomasoni, Marianna Adamo, Carlo Lombardi, et al.
ESC Heart Failure (2019) Vol. 6, Iss. 6, pp. 1105-1127
Open Access | Times Cited: 214
Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor
Jacob A. Udell, Žhong Yuan, Toni Rush, et al.
Circulation (2017) Vol. 137, Iss. 14, pp. 1450-1459
Open Access | Times Cited: 207
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial
Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca, et al.
American Heart Journal (2018) Vol. 200, pp. 83-89
Closed Access | Times Cited: 180
European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure
Petar Seferović, Andrew J.S. Coats, Piotr Ponikowski, et al.
European Journal of Heart Failure (2019) Vol. 22, Iss. 2, pp. 196-213
Open Access | Times Cited: 156
SGLT‐2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects
Carolyn S.P. Lam, Chanchal Chandramouli, Vineeta Ahooja, et al.
Journal of the American Heart Association (2019) Vol. 8, Iss. 20
Open Access | Times Cited: 153
SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis
Rhanderson Cardoso, Fabrissio P. Graffunder, Caique M. P. Ternes, et al.
EClinicalMedicine (2021) Vol. 36, pp. 100933-100933
Open Access | Times Cited: 118
Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure
John J.V. McMurray, Piotr Ponikowski, Geremia B. Bolli, et al.
JACC Heart Failure (2017) Vol. 6, Iss. 1, pp. 8-17
Open Access | Times Cited: 158
The potential role and rationale for treatment of heart failure with sodium–glucose co‐transporter 2 inhibitors
Javed Butler, Carine E. Hamo, Gerasimos Filippatos, et al.
European Journal of Heart Failure (2017) Vol. 19, Iss. 11, pp. 1390-1400
Open Access | Times Cited: 157
Class effects of SGLT2 inhibitors on cardiorenal outcomes
Aaron Y. Kluger, Kristen M. Tecson, Andy Lee, et al.
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 135
Interaction Between the Sodium‐Glucose–Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects
Christopher S. Wilcox, Wen Shen, David W. Boulton, et al.
Journal of the American Heart Association (2018) Vol. 7, Iss. 4
Open Access | Times Cited: 122
Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation
Adriana Marton, Tatsuroh Kaneko, Jean‐Paul Kovalik, et al.
Nature Reviews Nephrology (2020) Vol. 17, Iss. 1, pp. 65-77
Closed Access | Times Cited: 109
Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes
Franco Cosmi, Li Shen, Michela Magnoli, et al.
European Journal of Heart Failure (2018) Vol. 20, Iss. 5, pp. 888-895
Open Access | Times Cited: 105
Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence
Alberto Palazzuoli, Massimo Iacoviello
Heart Failure Reviews (2022) Vol. 28, Iss. 3, pp. 585-596
Open Access | Times Cited: 50
Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond
Pieter Martens, Chantal Mathieu, Frederik H. Verbrugge
Current Treatment Options in Cardiovascular Medicine (2017) Vol. 19, Iss. 3
Closed Access | Times Cited: 84
Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies
Guntram Schernthaner, Marie Helene Schernthaner-Reiter
Diabetologia (2018) Vol. 61, Iss. 7, pp. 1503-1516
Open Access | Times Cited: 76
The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction
Jonathan Newman, Anish Vani, José O. Alemán, et al.
Journal of the American College of Cardiology (2018) Vol. 72, Iss. 15, pp. 1856-1869
Open Access | Times Cited: 76
Stress hyperglycemia, cardiac glucotoxicity, and critically ill patient outcomes current clinical and pathophysiological evidence
Marc Scheen, Raphaël Giraud, Karim Bendjelid
Physiological Reports (2021) Vol. 9, Iss. 2
Open Access | Times Cited: 43
Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study
Hirotsugu Yamada, Atsushi Tanaka, Kenya Kusunose, et al.
Cardiovascular Diabetology (2017) Vol. 16, Iss. 1
Open Access | Times Cited: 55
The difference in referencing in Web of Science, Scopus, and Google Scholar
Markus S. Anker, Sara Hadzibegovic, Alessia Lena, et al.
ESC Heart Failure (2019) Vol. 6, Iss. 6, pp. 1291-1312
Open Access | Times Cited: 54
Pathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy
Núria Alonso, Pedro Moliner, Dı́dac Mauricio
Advances in experimental medicine and biology (2017), pp. 197-217
Closed Access | Times Cited: 51
Comparative Cardiovascular Outcomes of SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials
Yu Jiang, Pingping Yang, Linghua Fu, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 26
Empagliflozin, calcium, and SGLT1/2 receptor affinity: another piece of the puzzle
Stefan D. Anker, Javed Butler
ESC Heart Failure (2018) Vol. 5, Iss. 4, pp. 549-551
Open Access | Times Cited: 39
Page 1 - Next Page

Scroll to top